# US 2017/0281651 A1 · Concomitant administration of glucocorticoid receptor modulators and cyp3a or steroidogenesis inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281651 A1
- Document ID: US20170281651A1
- Status: Published application
- Kind: A1
- Application number: 15/627,368
- Filed: 2017-06-19
- Published: 2017-10-05
- Earliest claimed: 2017-03-01
- Assignees: Corcept Therapeutics, Inc.
- Applicants: Corcept Therapeutics, Inc.
- Inventors: Joseph K. Belanoff
- Web page: https://patentgrep.com/patent/US20170281651A1

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/46: for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of a glucocorticoid receptor antagonist (GRA) and steroidogenesis inhibitors, and by concomitant administration of a GRA and CYP3A inhibitors. Applicant provides methods of treating diseases including Cushing's syndrome and hormone-sensitive cancers by concomitant administration of mifepristone and ketoconazole. Subjects treated with CYP3A inhibitors or steroidogenesis inhibitors may suffer from toxicity or other serious adverse reactions; concomitant administration of other drugs would be expected to increase the risk of such toxicity and adverse reactions. Applicant has surprisingly found that GRAs may be administered to subjects receiving CYP3A inhibitors or steroidogenesis inhibitors such as ketoconazole without increasing risk adverse reactions; for example, Applicant has found that mifepristone may be concomitantly administered with ketoconazole (a CYP3A inhibitor and a steroidogenesis inhibitor), providing safe concomitant administration of the GRA and ketoconazole. In embodiments, the GRA dose may be reduced.

## Claims

### Claim 1

A method of treating Cushing's syndrome in a patient who is taking a glucocorticoid receptor antagonist (GRA) comprising reducing the daily dose of said GRA from an original dose to an adjusted dose that is at least 25% less than said original dose when the patient is receiving concomitant administration of a CYP3A inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein i) said original dose is 600 milligrams (mg) per day of said GRA, and said adjusted dose is 300 mg per day of said GRA; (ii) said original dose is 900 mg per day of said GRA, and said adjusted dose is 600 mg per day of said GRA; or iii) said original dose is 1200 mg per day of said GRA, and said adjusted dose is selected from 600 mg per day and 900 mg per day of said GRA.

### Claim 3 (depends on 1)

The method of claim 1, wherein said adjusted dose is selected from 300 mg per day and 600 mg per day of said GRA, further comprising titrating the adjusted dose to a maximum of 900 mg per day of said GRA.

### Claim 4 (depends on 1)

The method of claim 1, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 5 (depends on 2)

The method of claim 2, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 6 (depends on 3)

The method of claim 3, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 7 (depends on 1)

The method of claim 1, wherein said CYP3A inhibitor is ketoconazole.

### Claim 8 (depends on 4)

The method of claim 4, wherein said CYP3A inhibitor is ketoconazole.

### Claim 9 (depends on 5)

The method of claim 5, wherein said CYP3A inhibitor is ketoconazole.

### Claim 10

A method of treating symptoms associated with elevated cortisol levels in a patient who is taking a glucocorticoid receptor antagonist (GRA) comprising reducing the daily dose of said GRA from an original dose to an adjusted dose that is at least 25% less than said original dose when the patient is receiving concomitant administration of a CYP3A inhibitor.

### Claim 11 (depends on 10)

The method of claim 10, wherein said original dose is selected from 600 milligrams (mg), 900 mg, and 1200 mg per day of said GRA, and said adjusted dose is an amount of said GRA that is 300 mg or 600 mg less per day of said GRA, further comprising titrating the adjusted dose of GRA to a maximum of 900 mg per day of said GRA.

### Claim 12 (depends on 10)

The method of claim 10, wherein said original dose is 600 milligrams (mg) of per day of said GRA, and said adjusted dose is 300 mg per day of said GRA, further comprising titrating the adjusted dose to a maximum of 900 mg per day of said GRA.

### Claim 13 (depends on 10)

The method of claim 10, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 14 (depends on 11)

The method of claim 11, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 15 (depends on 12)

The method of claim 12, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 16 (depends on 10)

The method of claim 10, wherein said CYP3A inhibitor is ketoconazole.

### Claim 17 (depends on 13)

The method of claim 13, wherein said CYP3A inhibitor is ketoconazole.

### Claim 18 (depends on 14)

The method of claim 14, wherein said CYP3A inhibitor is ketoconazole.

### Claim 19

A method of controlling hyperglycemia secondary to hypercortisolism in a patient with endogenous Cushing's syndrome who is taking a glucocorticoid receptor antagonist (GRA) comprising reducing the daily dose of said GRA from an original dose to an adjusted dose that is at least 25% less than said original dose when the patient is receiving concomitant administration of a CYP3A inhibitor.

### Claim 20 (depends on 10)

The method of claim 10, wherein said original dose is selected from 600 milligrams (mg), 900 mg, and 1200 mg per day of said GRA, and said adjusted dose is an amount of said GRA that is 300 mg or 600 mg less per day of said GRA, further comprising titrating the adjusted dose of GRA to a maximum of 900 mg per day of said GRA.

### Claim 21 (depends on 19)

The method of claim 19, wherein said original dose is 600 milligrams (mg) per day of said GRA, and said adjusted dose is 300 mg per day of said GRA, further comprising titrating the adjusted dose to a maximum of 900 mg per day of said GRA.

### Claim 22 (depends on 19)

The method of claim 19, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 23 (depends on 20)

The method of claim 20, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 24 (depends on 21)

The method of claim 21, wherein said GRA is mifepristone and said CYP3A inhibitor is a strong CYP3A inhibitor.

### Claim 25 (depends on 19)

The method of claim 19, wherein said CYP3A inhibitor is ketoconazole.

### Claim 26 (depends on 22)

The method of claim 22, wherein said CYP3A inhibitor is ketoconazole.

### Claim 27 (depends on 23)

The method of claim 23, wherein said CYP3A inhibitor is ketoconazole.

### Claim 28

A method of controlling hyperglycemia secondary to hypercortisolism in a patient with endogenous Cushing's syndrome comprising administering a daily dose of mifepristone selected from 900 milligrams (mg) mifepristone, 600 mg mifepristone, and 300 mg mifepristone when the patient is receiving concomitant administration of a CYP3A inhibitor.

### Claim 29 (depends on 28)

The method of claim 28, wherein the CYP3A inhibitor is ketoconazole.

### Claim 30 (depends on 29)

The method of claim 29, wherein said daily dose of mifepristone is selected from 600 milligrams (mg) per day and 300 mg per day of mifepristone, the method further comprising titrating the daily dose up to a titrated dose of no greater than 900 mg per day of mifepristone.
